LTMP copy

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 15/12, 15/57, C07K 14/47, C12N 9/64, A61K 38/48, 38/17, 47/48 — A2

(11) International Publication Number: WO 96/07738

(43) International Publication Date: 14 March 1996 (14.03.96)

(21) International Application Number: PCT/GB95/02121

(22) International Filing Date: 8 September 1995 (08.09.95)

(30) Priority Data:

9418147.6	8 September 1994 (08.09.94)	GB
9509102.1	4 May 1995 (04.05.95)	GB

(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).

Published
Without international search report and to be republished upon receipt of that report.

SG 9700765-2

(71) Applicant *(for all designated States except US)*: IMUTRAN LIMITED [GB/GB]; 21 Holborn Viaduct, London EC1A 2DY (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: HARRISON, Richard, Alexander [GB/GB]; MRC Centre, Hills Road, Cambridge CB2 2QH (GB). FARRIES, Timothy, Charles [GB/GB]; MRC Centre, Hills Road, Cambridge CB2 2QH (GB).

(74) Agents: WHITE, Martin, Paul et al.; Kilburn & Strode, 30 John Street, London WC1N 2DD (GB).

(54) Title: MODIFIED HUMAN C3 PROTEINS

(57) Abstract

Native complement pathway proteins modified such that the protein is capable of forming a stable C3 convertase. Preferably the modified protein is a modified human C3 protein. DNA sequences encoding such proteins are also provided, together with DNA constructs. Conjugates comprising such proteins and a specific binding moiety, for example an antibody, are also described, as are uses of such proteins and/or conjugates in therapy.